Lydia Celine Tansem Buer
- MD; PhD
- +47 23 02 74 58
Education
MD University of Oslo (2012)
Current position
PhD student, Department of gastroenterology, Oslo University Hospital
Publications 2023
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 1-11 (in press)
DOI 10.1080/00365521.2023.2176252, PubMed 36799155
Publications 2019
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312
Publications 2018
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793
Publications 2017
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339
Publications 2012
How does kidney transplantation affect the relationship between donor and recipient?
Tidsskr Nor Laegeforen, 132 (1), 41-3
DOI 10.4045/tidsskr.10.1403, PubMed 22240827